Epilepsiae

The project intends to develop an intelligent alarming system, transportable by the patient, measuring the brain dynamical activity, capable of predicting the seizures, allowing the patient to assess the risk of his actual situation and improving his safety The system is based on multi-signal information (EEG, ECG and others), intelligent data processing and wireless communications.

The project will develop knowledge (in data analysis), algorithms (of seizure prediction) and technologies (of data acquisition and wireless transmission) that integrated into an intelligent system will be an important step forward in economical affordable personal healthcare systems for neurological applications. A distributed European Epilepsy Database will also be built by the project, including all the available information about epileptic patients, allowing semantic mining based on multi-modal, multisignal and multidimensional data.

The Epilepsiae consortium consists of seven partners from 4 countries: 3 academic, 3 clinics, 1 industrial SME company, covering the whole value chain from theoretical conception to market products and final users.

For further information, please visit:
http://www.epilepsiae.eu

Project co-ordinator:
FACULDADE CIENCIAS E TECNOLOGIA DA UNIVERSIDADE DE COIMBRA (Portugal)

Partners:

  • ALBERT-LUDWIGS-UNIVERSITAET FREIBURG (Germany)
  • MICROMED S.P.A. (Italy)
  • UNIVERSITAETSKLINIKUM FREIBURG (Germany)
  • CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
  • HOSPITAIS DA UNIVERSIDADE DE COIMBRA (Portugal)

Timetable: from 01/2008 – to 12/2010

Total cost: €4.153.125

EC funding: €2.919.805

Programme Acronym: FP7-ICT

Subprogramme Area: Advanced ICT for risk assessment and patient safety

Contract type: Collaborative project (generic)

Related news article:

Most Popular Now

The Future of Medicine is Data

At the 2023 Annual J.P. Morgan Healthcare Conference, Owkin Co-founder and CEO Thomas Clozel, MD will outline how data is the future of medicine - from the development of new...

Study Surveys Landscape of Apps Built on…

A study led by Regenstrief Institute Research Scientist Titus K. Schleyer, DMD, PhD, is among the first to survey the current landscape of FHIR® apps, providing a snapshot of how...

New Computer Program 'Learns' to Identif…

Genetic mutations cause hundreds of unsolved and untreatable disorders. Among them, DNA mutations in a small percentage of cells, called mosaic mutations, are extremely difficult to detect because they exist...

Applications Open for SpinLab Accelerato…

The start-up accelerator supports entrepreneurial and innovative teams that want to grow sustainably and successfully scale their business model. With a strong hands-on mentality and a lot of passion, the...

Bayer to Accelerate Drug Discovery with …

Bayer AG and Google Cloud today announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-developed accelerators designed to run...

Allscripts Announces Corporate Name Chan…

Allscripts Healthcare Solutions, Inc. announced that, effective January 1, 2023, it has changed its name to Veradigm Inc. (NASDAQ: MDRX). Allscripts had been transitioning its solutions to the Veradigm brand...

220M€ Investment in Testing and Experime…

To make the EU the place where AI excellence thrives from the lab to the market, the European Union is setting up world-class Testing and Experimentation Facilities (TEFs) for AI. Together...

AI Tool Developed to Predict Risk of Lun…

Lung cancer is the leading cause of cancer death in the United States and around the world. Low-dose chest computed tomography (LDCT) is recommended to screen people between 50 and...

Artificial Nerve Cells - Almost Like Bio…

Researchers at Linköping University (LiU), Sweden, have created an artificial organic neuron that closely mimics the characteristics of biological nerve cells. This artificial neuron can stimulate natural nerves, making it...

Bayer Acquires Blackford Analysis Ltd. B…

Bayer announced the acquisition of the global strategic imaging AI platform and solutions provider Blackford Analysis Ltd. The acquisition is part of Bayer's strategy to drive innovation in radiology, including...

For Shared Decision-Making, Telemedicine…

Telemedicine may be just as effective as in-person visits when it comes to shared decision-making and communication for patients undergoing a first-time surgery consultation, according to a study published as...

Veradigm Announces Strategic Investment …

Veradigm Inc. (NASDAQ: MDRX), formerly Allscripts Healthcare Solutions, Inc., announced an investment in Holmusk, a global behavioral health real-world evidence and data analytics company, as part of Holmusk's $45 million...